How Scott Gottlieb may transform the FDA’s approach to stem cells
The Trump FDA commissioner nominee Dr. Scott Gottlieb could dramatically alter how the agency regulates investigational stem cell therapies. How might such changes unfold? There are potential upsides and downsides to the seismic shift that could be in the offing. Gottlieb has written in the past about his perception of FDA over-regulation of stem cells such […]
How Scott Gottlieb may transform the FDA’s approach to stem cells Read More »